3025 Chemical Road, Suite 100, Plymouth Meeting, PA 19462 Phone: 215-690-0300 Fax: 215-690-0280 Copyright © 2021 National Comprehensive Cancer Network, All Rights Reserved. No portion of this Site or any NCCN Content may be copied, transferred, reproduced, modified, or otherwise used for any purpose without NCCN’s express written permission.See Legal Notices Section for…
The Oncologic Drugs Advisory Committee determined that minimal residual disease could serve as an accelerated approval end point in multiple myeloma clinical trials.
The Oncologic Drugs Advisory Committee determined that minimal residual disease could serve as an accelerated approval end point in multiple myeloma clinical trials.
The Oncologic Drugs Advisory Committee determined that minimal residual disease could serve as an accelerated approval end point in multiple myeloma clinical trials.
During the morning session, the Committee will discuss supplemental biologics license application (sBLA) 125746.74 for CARVYKTI (ciltacabtagene autoleucel), …
Myeloma is a common haematological malignancy in which adverse skeletal related events are frequently seen. Over recent years, treatment for myeloma has evolved leading to…
Abstract. Abstract 4079Background:. In multiple myeloma (MM), lenalidomide has impressive clinical activity in patients with both relapsed/refractory and newly
In our third and final installment of the Cardinal Healthᵀᴹ 2023 American Society of Hematology (ASH) Annual Meeting News Briefs, we highlight the top abstracts…
Claims of hypocrisy miss the mark in a couple of ways.
CAR T-cell therapy and novel agents are being used in earlier treatment lines for NHL, but how do they fit into the evolving treatment landscape?…
Despite a happy oncologist being our most precious resource, physician burnout appears to be at an all-time high, and the topic is now a part…
